Torvik D, Madsbu H P
Br J Clin Pharmacol. 1986;21 Suppl 1(Suppl 1):69S-75S. doi: 10.1111/j.1365-2125.1986.tb02856.x.
A 12-week double-blind study was performed to compare the safety and efficacy of doxazosin, prazosin and placebo in 172 patients with essential hypertension. According to response, patients received doxazosin 1-16 mg once daily, prazosin 0.5-10 mg twice daily, or placebo. Mean final daily doses were doxazosin 11.3 mg and prazosin 13.8 mg. Doxazosin once daily and prazosin twice daily both produced statistically significant reductions in both standing and supine blood pressures when compared with placebo. No significant differences between treatments were recorded for standing and supine heart rates. Doxazosin, prazosin and placebo all had a similar effect on plasma lipid profiles, i.e. an increase in HDL/total cholesterol of approximately 10%. The differences between treatments were not statistically significant. The HDL/total cholesterol ratio significantly increased from baseline to the end of treatment for all three groups, the decrease in triglycerides being statistically significant only in the doxazosin-treated group.
一项为期12周的双盲研究对172例原发性高血压患者进行了多沙唑嗪、哌唑嗪和安慰剂的安全性及有效性比较。根据反应情况，患者分别接受每日一次1-16毫克的多沙唑嗪、每日两次0.5-10毫克的哌唑嗪或安慰剂治疗。最终平均日剂量为多沙唑嗪11.3毫克、哌唑嗪13.8毫克。与安慰剂相比，每日一次的多沙唑嗪和每日两次的哌唑嗪在站立位和仰卧位血压方面均产生了具有统计学意义的降低。站立位和仰卧位心率在各治疗组之间未记录到显著差异。多沙唑嗪、哌唑嗪和安慰剂对血脂谱的影响相似，即高密度脂蛋白/总胆固醇升高约10%。各治疗组之间的差异无统计学意义。三组患者从基线到治疗结束时高密度脂蛋白/总胆固醇比值均显著升高，仅多沙唑嗪治疗组甘油三酯降低具有统计学意义。
